Mint3-mediated L1CAM expression in fibroblasts promotes cancer cell proliferation via integrin α5β1 and tumour growth

Oncogenesis

Volumn 6, Issue 5, 2017, Pages

  Nakaoka, H J ^a   Tanei, Z ^a,b   Hara, T ^a   Weng, J S ^a   Kanamori, A ^a   Hayashi, T ^a   Sato, H ^c   Orimo, A ^d   Otsuji, K ^e   Tada, K ^e   Morikawa, T ^b   Sasaki, T ^b   Fukayama, M ^b   Seiki, M ^c   Murakami, Y ^a   Sakamoto, T ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; MATRIX METALLOPROTEINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 1; MUNC18 1 INTERACTING PROTEIN 3; NERVE CELL ADHESION MOLECULE L1; PROTEIN; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5;

A-431 CELL LINE; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CELL ACTIVATION; CELL COMMUNICATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FIBROBLAST; GENE EXPRESSION; GLYCOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MDA-MB-231 CELL LINE; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 85024095451     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2017.27     Document Type: Article

References (50)

1. Gascard P, Tlsty TD. Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. Genes Dev 2016; 30: 1002-1019.
2. Ohlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. J Exp Med 2014; 211: 1503-1523.
3. Polanska UM, Orimo A. Carcinoma-associated fibroblasts: non-neoplastic tumourpromoting mesenchymal cells. J Cell Physiol 2013; 228: 1651-1657.
4. Luo H, Tu G, Liu Z, Liu M. Cancer-associated fibroblasts: A multifaceted driver of breast cancer progression. Cancer Lett 2015; 361: 155-163.
5. Ishii G, Ochiai A, Neri S. Phenotypic and functional heterogeneity of cancerassociated fibroblast within the tumour microenvironment. Adv Drug Deliv Rev 2016; 99: 186-196.
6. Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 2014; 25: 719-734.
7. Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 2014; 25: 735-747.
8. Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 2010; 40: 294-309.
9. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008; 30: 393-402.
10. Hara T, Mimura K, Abe T, Shioi G, Seiki M, Sakamoto T. Deletion of the Mint3/Apba3 gene in mice abrogates macrophage functions and increases resistance to lipopolysaccharide-induced septic shock. J Biol Chem 2001; 286: 32542-32551.
11. Sakamoto T, Niiya D, Seiki M. Targeting the Warburg effect that arises in tumour cells expressing membrane type-1 matrix metalloproteinase. J Biol Chem 2011; 286: 14691-14704.
12. Sakamoto T, Seiki M. Mint3 enhances the activity of hypoxia-inducible factor-1 (HIF-1) in macrophages by suppressing the activity of factor inhibiting HIF-1. J Biol Chem 2009; 284: 30350-30359.
13. Sakamoto T, Weng JS, Hara T, Yoshino S, Kozuka-Hata H, Oyama M et al. Hypoxiainducible factor 1 regulation through cross talk between mTOR and MT1-MMP. Mol Cell Biol 2014; 34: 30-42.
14. Sakamoto T, Seiki M. A membrane protease regulates energy production in macrophages by activating hypoxia-inducible factor-1 via a non-proteolytic mechanism. J Biol Chem 2010; 285: 29951-29964.
15. Okamoto M, Sudhof TC. Mint 3: A ubiquitous mint isoform that does not bind to munc18-1 or-2. Eur J Cell Biol 1998; 77: 161-165.
16. Nakaoka HJ, Hara T, Yoshino S, Kanamori A, Matsui Y, Shimamura T et al. NECAB3 promotes activation of hypoxia-inducible factor-1 during normoxia and enhances tumourigenicity of cancer cells. Sci Rep 2016; 6: 22784.
17. Sakamoto T, Seiki M. Cytoplasmic tail of MT1-MMP regulates macrophage motility independently from its protease activity. Genes Cells 2009; 14: 617-626.
18. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumour microenvironment. Cell 2010; 141: 52-67.
19. Itoh Y, Seiki M. MT1-MMP: A potent modifier of pericellular microenvironment. J Cell Physiol 2006; 206: 1-8.
20. Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2012; 12: 9-22.
21. Semenza GL. HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 2010; 20: 51-56.
22. Cramer T, Yamanishi Y, Clausen BE, Förster I, Pawlinski R, Mackman N et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 2003; 112: 645-657.
23. Hara T, Mimura K, Seiki M, Sakamoto T. Genetic dissection of proteolytic and nonproteolytic contributions of MT1-MMP to macrophage invasion. Biochem Biophys Res Commun 2011; 413: 277-281.
24. Valiente M, Obenauf AC, Jin X, Chen Q, Zhang XH, Lee DJ et al. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 2014; 156: 1002-1016.
25. Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P, Brabletz T et al. L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol 2005; 168: 633-642.
26. Ben Q, An W, Fei J, Xu M, Li G, Li Z et al. Downregulation of L1CAM inhibits proliferation, invasion and arrests cell cycle progression in pancreatic cancer cells in vitro. Exp Ther Med 2014; 7: 785-790.
27. Hai J, Zhu CQ, Bandarchi B, Wang YH, Navab R, Shepherd FA et al. L1 cell adhesion molecule promotes tumourigenicity and metastatic potential in non-small cell lung cancer. Clin Cancer Res 2012; 18: 1914-1924.
28. Trietsch MD, Oonk MH, Hawinkels LJ, Bor R, van Eendenburg JD, Ivanova Z et al. Prognostic value and clinicopathologic characteristics of L1 cell adhesion molecule (L1CAM) in a large series of vulvar squamous cell carcinomas. Oncotarget 2016; 7: 26192-26205.
29. Schroder C, Schumacher U, Fogel M, Feuerhake F, Müller V, Wirtz RM et al. Expression and prognostic value of L1-CAM in breast cancer. Oncol Rep 2009; 22: 1109-1117.
30. Helm O, Mennrich R, Petrick D, Goebel L, Freitag-Wolf S, Röder C et al. Comparative characterization of stroma cells and ductal epithelium in chronic pancreatitis and pancreatic ductal adenocarcinoma. PLoS ONE 2014; 9: e94357.
31. Zhang H, Wong CC, Wei H, Gilkes DM, Korangath P, Chaturvedi P et al. HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs. Oncogene 2012; 31: 1757-1770.
32. Luo W, Chang R, Zhong J, Pandey A, Semenza GL. Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression. Proc Natl Acad Sci USA 2012; 109: E3367-E3376.
33. Kiefel H, Pfeifer M, Bondong S, Hazin J, Altevogt P. Linking L1CAM-mediated signaling to NF-kappaB activation. Trends Mol Med 2011; 17: 178-187.
34. Kiefel H, Bondong S, Hazin J, Ridinger J, Schirmer U, Riedle S et al. L1CAM: A major driver for tumour cell invasion and motility. Cell Adh Migr 2012; 6: 374-384.
35. Khalili P, Arakelian A, Chen G, Plunkett ML, Beck I, Parry GC et al. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther 2006; 5: 2271-2280.
36. Stoeltzing O, Liu W, Reinmuth N, Fan F, Parry GC, Parikh AA et al. Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer 2003; 104: 496-503.
37. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumour growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335-348.
38. Kojima Y, Acar A, Eaton EN, Mellody KT, Scheel C, Ben-Porath I et al. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumour-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci USA 2010; 107: 20009-20014.
39. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008; 14: 518-527.
40. Stawowy P, Margeta C, Kallisch H, Seidah NG, Chrétien M, Fleck E et al. Regulation of matrix metalloproteinase MT1-MMP/MMP-2 in cardiac fibroblasts by TGF-beta1 involves furin-convertase. Cardiovasc Res 2004; 63: 87-97.
41. Ries C, Egea V, Karow M, Kolb H, Jochum M, Neth P et al. MMP-2 and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines. Blood 2007; 109: 4055-4063.
42. Rajavashisth TB, Liao JK, Galis ZS, Tripathi S, Laufs U, Tripathi J et al. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J Biol Chem 1999; 274: 11924-11929.
43. Haas TL, Davis SJ, Madri JA. Three-dimensional type I collagen lattices induce coordinate expression of matrix metalloproteinases MT1-MMP and MMP-2 in microvascular endothelial cells. J Biol Chem 1998; 273: 3604-3610.
44. Quail DF, Joyce JA. Microenvironmental regulation of tumour progression and metastasis. Nat Med 2013; 19: 1423-1437.
45. Lu P, Weaver VM, Werb Z. The extracellular matrix: A dynamic niche in cancer progression. J Cell Biol 2012; 196: 395-406.
46. DiDonato JA, Mercurio F, Karin M. NF-kappaB and the link between inflammation and cancer. Immunol Rev 2012; 246: 379-400.
47. Ieguchi K, Tomita T, Omori T, Komatsu A, Deguchi A, Masuda J et al. ADAM12-cleaved ephrin-A1 contributes to lung metastasis. Oncogene 2014; 33: 2179-2190.
48. Wang J, Dong Y, Wang X, Ma H, Sheng Z, Li G et al. Expression of EphA1 in gastric carcinomas is associated with metastasis and survival. Oncol Rep 2010; 24: 1577-1584.
49. Yoshino S, Hara T, Weng JS, Takahashi Y, Seiki M, Sakamoto T. Genetic screening of new genes responsible for cellular adaptation to hypoxia using a genome-wide shRNA library. PLoS ONE 2012; 7: e35590.
50. Yoshino S, Hara T, Nakaoka HJ, Kanamori A, Murakami Y, Seiki M et al. The ERK signaling target RNF126 regulates anoikis resistance in cancer cells by changing the mitochondrial metabolic flux. Cell Discov 2016; 2: 16019.